Identifying Predictive Biomarkers for Head and Neck Squamous Cell Carcinoma Response

Area of Science:

• Oncology
• Immunology
• Biomarker Discovery

Background:

• Head and neck squamous cell carcinoma (HNSCC) has a 5-year survival rate of approximately 65%.
• Immunotherapy is a growing treatment modality for advanced HNSCC.
• Understanding the tumor immune microenvironment is crucial for personalized treatment strategies.

Purpose of the Study:

• To evaluate the expression profiles of CMTM6, PD-L1, CTLA-4, and FOXP3 in HNSCC.
• To correlate these marker expressions with patient outcomes and treatment responses.
• To identify potential prognostic and predictive signatures for HNSCC.

Main Methods:

• Expression profiling of CMTM6, PD-L1, CTLA-4, and FOXP3 in 177 HNSCC tumors (discovery cohort) and an independent validation cohort.
• Correlation analysis of marker expression with overall survival, progression-free survival, and response to radiotherapy, chemotherapy, and immunotherapy.
• Gene expression analysis in patients receiving immunotherapy.

Main Results:

• Higher CMTM6 expression was associated with longer overall survival in HNSCC patients, independent of treatment, and this was validated in a separate cohort.
• CMTM6 expression showed a predictive effect in patients receiving radiotherapy and correlated with PD-L1, CTLA-4, and FOXP3 positivity.
• Patients with CMTM6high/FOXP3high tumors exhibited the longest survival. PD-L1 positivity predicted longer progression-free survival in chemotherapy-treated patients. Lower CTLA-4 and FOXP3 levels correlated with immunotherapy response.

Conclusions:

• CMTM6 is a significant prognostic marker for HNSCC, associated with improved overall survival.
• The combination of CMTM6, PD-L1, CTLA-4, and FOXP3 expression presents a promising signature for predicting HNSCC patient outcomes.
• These findings support the potential for optimizing individualized treatment strategies in HNSCC based on immunomodulatory marker profiles.